Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2/3
Active, not recruiting
NCT02152982
| Condition | Glioblastoma, Gliosarcoma |
|---|
| Phase | Phase 2/3 |
|---|
| Sponsor | National Cancer Institute (NCI) |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 447 participants |
|---|
| Interventions | Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib |
|---|
| Start date | Dec 15, 2014 |
|---|
| Completion date | Dec 1, 2021 |
|---|
| Results posted | Apr 4, 2023 |
|---|
Summary
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.
Overall Survival (OS)
83 months · months
| Arm I (Temozolomide, Placebo) | 24.8 months |
|---|
| Arm II (Temozolomide, Veliparib) | 28.1 months |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
Other trials for this condition
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.